Genmab — Juni 2020
-
Ja men det er kun dose eskalering fasen de viser data fra. Ikke 2. del af studiet hvor det udelukkende er 48mg
-
og det er så ca 50 patienter de vil indrullere på 48mg (op til samlet 110 patienter)
-
-
Thanks E L, Citi were not dissatisfied with what they saw at ASCO then
-
Except for UBS and Citi all analysts are now behind the curve, there will come a large number of upgrades after the partner deal
-
Here is the link kkjoel https://www.streetinsider.
com/dr/news.php?id=16952064 -
-
I also think Dara First line approval and now Subcutaneous approval are key in my opinion and warrant upgrades on their own. We should not underestimate how many large investors only start buying in when a stock is de-risked. And in hind-sight covid may be the perfict time to introduce SC...
-
Genmab price target raised to $34 from $29 at H.C. Wainwright H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on Genmab to $34 from $29 and reiterates a Buy rating on the shares. The company last week announced positive top-line results for the combination of subcutaneous Darzalex plus cyclophosphamide, bortezomib and dexamethasone versus CyBorD alone from the Phase 3 ANDROMEDA trial, Selvaraju tells investors in a research note
The Fly | LANDING
Real-time market news, financial data, stock research, and portfolio tools from The Fly.
(thefly.com)
Highest is UBS and Citi: 2500.Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind